Sanofi's Rilzabrutinib Gains Regulatory Designations in Japan and U.S. for Rare Diseases
Sanofi's oral BTK inhibitor rilzabrutinib received orphan drug designation in Japan for IgG4-related disease and warm autoimmune hemolytic anemia, while also securing U.S. FDA breakthrough therapy designation for the rare anemia indication.